Abstract:While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that (1) CH is prevalent in relapsed follicular lymphoma (FL) and is associated with t-MN transformation. (2) Radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the prevalence and prognostic impact of CH on clinical outcomes in 58 heavily pre-treated FL patients who received RIT. Patients received a median of 4 lines of therapy before RIT. The prevalence of CH prior to RIT was 46%, while it was 67% (p=0.15) during the course of RIT and subsequent therapies in the paired samples. Fourteen (24%) patients developed t-MN. Patients with t-MN had a higher variant allele fraction (38% vs. 15%, p=0.02) and clonal complexity (p=0.03) than those without. The spectrum of CH differed from age-related CH, with a high prevalence of DNA damage repair and response pathway mutations, absence of spliceosome mutations, and a paucity of signaling mutations. While there were no clear clinical associations between RIT and t-MN, or overall survival, patients with t-MN had a higher mutant clonal burden, along with extensive chromosomal abnormalities (median survival 0.9 months). The baseline prevalence of CH is high, with a subsequent increase in prevalence on exposure to RIT and subsequent therapies. The high rates of t-MN with high clonal complexities and extensive chromosomal damage underscore the importance of better identifying and studying genotoxic stressors accentuated by these agents.

Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy